JP

Jaume Pons

President and CSO at ALX Oncology

Burlingame, California

Invests in

Stages:

Locations:

  • Min Investment:

    $20,000,000.00
  • Max Investment:

    $30,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • President and CSO

    2023

  • President and CEO

    2015 - 2023

    We are a clinical stage company dedicated to developing novel biologics that are both safe and efficacious for use in combination with anticancer antibodies to help the immune system eradicate cancer. More information at: http://alxoncology.com/

  • President and CEO

    2015 - 2023

2015

  • Venbio Venture partner

    2015

2007 - 2015

  • Pfizer SVP and Rinat CSO

    2009 - 2015

    CSO (Chief Scientific Officer) of Rinat (acquired by Pfizer) and reporting to Dr. Mikael Dolsten, M.D. President of Pfizer World Research and Development (WRD). I also served as SVP at Pfizer and member of the Pfizer WRD Leadership Team, served as Chief Technology Officer for Pfizer Biotherapeutics, member of Pfizer Senior Leadership Council and Pfizer South San Francisco Site Head.

  • VP and Rinat CSO

    2008 - 2009

  • Chief Scientific Officer, Rinat

    2007 - 2009

    I am responsible for Rinat. Rinat is a scientifically independent company within a new Biotherapeutic initiative of Pfizer: The Biotherapeutics and Bioinnovation Centre (BBC). Reporting to Corey Goodman, companies in the BBC keep most of their independence while work closely with Pfizer to expand the biotherapeutics portfolio, the result is an organization that combines Biotech spirit with Pfizer’s Research, Development and Commercial capabilities.

1999 - 2002

  • Scientist 2

    1999 - 2002

1996 - 1999

  • Posdoc (Kirsch lab)

    1996 - 1999